Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
Status:
Terminated
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
Patients with 3 or more adverse prognostic factors have a higher relapse rate. Significant
anti-tumor activity in Hodgkin's lymphoma has been reported with two new drugs:gemcitabine
and vinorelbine. The introduction of these new agents with their different mechanisms of
action into the Stanford V regimen may increase effectiveness while maintaining a favorable
toxicity profile with respect to fertility and a low risk of secondary leukemia. On this
basis, we propose a new regimen, Stanford VI, for patients with bulky and advanced HD with 3
or more risk factors.